Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12]
Title:
Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12]
Author:
Cristofanilli, Massimo Harbeck, Nadia Rugo, Hope S. Castrellon, Aurelio Joy, Anil Abraham Verma, Sunil Im, Seock-Ah Iyer, Shrividya Puyana Theall, Kathy Gauthier, Eric Huang, Xin Bartlett, Cynthia Huang Loibl, Sibylle Finn, Richard S.